GlassScriptPhysician profile
Joseph I Ameh
NPI 1225144579
$7,069.78
in general payments reported to CMS, 2019-2025
34 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $436 · 2021: $917 · 2022: $1,570 · 2023: $1,423 · 2024: $481 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $28.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.43 |
| Education | $28.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,126.78 | 2019-2025 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $884.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $585.27 | 2019-2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $531.52 | 2019-2025 | Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $493.91 | 2019-2025 | Dupixent |
| Genzyme Corporation | $403.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $393.12 | 2023-2025 | Glassia |
| Grifols USA, LLC | $301.31 | 2020-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $257.32 | 2019-2024 | |
| Inspire Medical Systems, INC. | $231.79 | 2022-2025 | Inspire |
| Insmed, INC. | $200.87 | 2019-2024 | Arikayce |
| Mylan Specialty L.P. | $197.98 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $174.43 | 2022-2023 | Airduo Digihaler |
| Genentech USA, INC. | $172.65 | 2019-2022 | |
| Pulmonx Corporation | $127.19 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $124.13 | 2022 | |
| Mallinckrodt Hospital Products INC. | $123.38 | 2022-2025 | Acthar |
| Gilead Sciences, INC. | $107.87 | 2023 | |
| Phadia US INC. | $106.61 | 2019 | |
| Electromed, INC. | $96.43 | 2021-2024 | Smartvest |
| Harmony Biosciences LLC | $76.16 | 2022-2025 | |
| Verona Pharma, INC. | $50.68 | 2025 | Ohtuvayre |
| Inogen, INC. | $46.94 | 2022-2024 | |
| Philips North America LLC | $40.94 | 2019 | |
| Allergan, INC. | $38.23 | 2019 | |
| Ethicon INC. | $36.04 | 2019 | |
| Axsome Therapeutics, INC. | $28.20 | 2024 | Sunosi |
| Fisher & Paykel Healthcare INC | $20.57 | 2025 | Fisher & Paykel Healthcare |
| Novartis Pharmaceuticals Corporation | $17.55 | 2023 | |
| Mallinckrodt Enterprises LLC | $16.77 | 2019 | |
| Shire North American Group INC | $15.79 | 2019 | |
| Tactile Systems Technology INC | $15.71 | 2025 | Nimbl, Flexitouch Plus |
| Avadel Cns Pharmaceuticals, LLC | $13.85 | 2024 | Lumryz |
| Sunovion Pharmaceuticals INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ameh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.